Navigation Links
Agendia's Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
Date:12/13/2008

HUNTINGTON BEACH, California and AMSTERDAM, December 13 /PRNewswire/ -- Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.

HER2+ patients are commonly identified as high risk, yet MammaPrint was able to identify a low risk subgroup of HER2+ patients, who subsequently experienced a 10 year disease-free survival of close to 90 percent even in the absence of (neo)adjuvant trastuzumab (Herceptin(R)) and chemotherapy. Additionally, in a subgroup of highly endocrine responsive HER2/NEU positive patients, MammaPrint(R) low risk patients had no relapse.

The results were presented by Dr. Michael Knauer during the 2008 San Antonio Breast Cancer Symposium (SABCS). In the study population of 169 HER2+ patients MammaPrint(R) classified 16 percent of patients as having a good prognosis signature with a 10-year distant disease-free survival (DDFS) of 89 percent, compared to 84 percent of patients classified as having a poor prognosis signature with a DDFS of 64 percent.

MammaPrint(R)'s robustness is underscored by the 70 gene panel unique to the test and a resulting gene profile that covers all molecular pathways associated with breast cancer. HER2/NEU-overexpression is observed in 15-20 percent of invasive breast cancers and is widely considered to be a negative prognostic factor. As a result, current treatment guidelines classify all HER2-positive breast cancer patients at high risk of relapse, and recommend trastuzumab and chemotherapy.

MammaPrint(R) accurately identified a subgroup of patients with a good clinical outcome in HER2+ early breast cancer. These patients will be further studied in the ongoing MINDACT-trial (Microarra
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
2. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
3. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
4. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
5. New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
6. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
7. New Breast Imaging Technology Targets Hard-to-Detect Cancers
8. New Mammography Technology Effective in Detecting Breast Cancer
9. Siemens Introduces New Standard of Care for Breast Ultrasound
10. Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 3SBio Inc., ("3SBio") a leading biotechnology ... focusing on researching, developing, manufacturing and marketing biopharmaceutical ... an exclusive license agreement with JenKem Technology Co., ... in Mainland China of PEG-irinotecan, a long-acting polymer-drug ... over-expressed in many solid tumors, including colorectal, ovarian, ...
(Date:9/16/2014)... OAKLAND, Calif. , Sept. 16, 2014  Chairman ... that Richard (Dick) Daniels will assume the ... Foundation Hospitals and Health Plan, Inc., effective immediately. ... developing and implementing technological advancements that advance the high-quality ... members," Tyson said. " Dick Daniels has extensive ...
(Date:9/16/2014)... Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... all of the outstanding shares of Auxilium Pharmaceuticals, Inc. (NASDAQ: ... $28.10 in a cash and stock transaction valued at $2.2 ... to Auxilium,s closing price on September 16, 2014 and a ... for the previous 30 days.  Under the terms of the ...
Breaking Medicine Technology:3SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 23SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 33SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 43SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China 5Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Name Interim Chief Information Officer 2Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 2Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 3Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 4Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 5Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 6Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock 7
... KineMed Inc., a,pathway-based drug discovery and development ... of an investigational agent,to regenerate nerve cells in ... cognition and mood. The agent, part of a ... a behavioral test in a,preclinical model. The findings ...
... am ET, BEDMINSTER, N.J., Oct. 11 ... top-line results from,the company,s Phase 3 study of ... 83 patients with short bowel,syndrome (SBS) received either ... dose (0.10 mg/kg/day) or placebo. The,clinical efficacy endpoint ...
Cached Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 2Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 3Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 4Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 5Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 6Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study 7
(Date:9/17/2014)... Diabetes currently has no cure. According to an ... made several breakthroughs in search for a ... indicates that cure for diabetes is still many years ... forward-thinking entrepreneurs and health professionals who made strides in ... Kenneth Pullman is one of the individuals with genuine ...
(Date:9/17/2014)... 2014 Skin management experts™ at ... of the first in the USA to introduce a ... to minimize the appearance of vertical chest lines and ... with the first FDA-cleared ultrasound based facial procedure to ... have expanded their brand into tightening and smoothing the ...
(Date:9/17/2014)... AURORA, Colo. (PRWEB) September 17, 2014 ... American Sentinel University offers tips to health IT professionals ... , A recent study by HIMSS shows demand ... high and a candidate’s skill set is the differentiating ... is that of an IT professional that has clinical ...
(Date:9/17/2014)... 2014 Lee Berman, a seasoned veteran ... appearing on The Balancing Act® airing on Lifetime Television®. ... The segment will premiere on September 19 and re-air ... airing on Lifetime Television®' with show host Julie Moran. ... for over a decade and is the Director of ...
(Date:9/17/2014)... Kingston, NY (PRWEB) September 17, 2014 ... style of wellness to the lineup at Techmanity, a ... as “the next generation of tech events,” Techmanity will ... Voom is excited to join the ranks of Cisco, ... this first ever Silicon Valley Technology Conference. , Voom ...
Breaking Medicine News(10 mins):Health News:Discover a Safe and Effective Treatment for Diabetes with The Diabetes Protocol – Vinamy 2Health News:FACE Skincare Medical Wellness Debuts Ultherapy Décolletage Treatment 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 2Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 3Health News:American Sentinel University Offers Tips to Health IT Professionals for Gaining Competitive Edge in the Job Market 4Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2Health News:Health and Wellness Startup Voom Announces Sponsorship at Techmanity 2
... over-the-counter drug might reverse genetic process that leads to ... -- Researchers may have found an easy way to ... stages, as well as a way to reverse the ... over-the-counter drug. , "It,s incredibly, incredibly exciting," said ...
... the number of older Americans who delay retirement is likely ... a trend that should help ease the financial challenges facing ... Corporation study. While government projections suggest the number of ... the coming decade, RAND researchers say a more likely scenario ...
... Be ... , ... Each year, millions of Americans wait to file their federal income tax returns until the ... fast approaching, leading sleep advice web site SleepBetter.org is offering some tips to ...
... ... released version 4.3 of Replay, the award-winning, next generation backup and disaster recovery software ... Reston, ... of Replay, the award-winning, next generation backup and disaster recovery software solution. Because ...
... a condition in which the eyes turn outward while looking ... and is less common than esotropia, where the eyes turn ... of the American Journal of Ophthalmology , researchers from ... patients with intermittent exotropia over a 20-year period and found ...
... ... Suite of International Hosting and Managed Services. , ... Mississauga, Ontario (PRWEB) April 7, 2010 ... announced that it has launched the first international, multi-infrastructure cloud computing service ...
Cached Medicine News:Health News:Simple Test May Spot Early Lung Cancer 2Health News:Simple Test May Spot Early Lung Cancer 3Health News:Delayed retirement among Americans may bolster future of Social Security and Medicare, study finds 2Health News:Delayed retirement among Americans may bolster future of Social Security and Medicare, study finds 3Health News:Last-Minute Tax Tip: Get a Good Night's Sleep 2Health News:Last-Minute Tax Tip: Get a Good Night's Sleep 3Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 3Health News:90 percent of children with intermittent exotropia will become nearsighted by 20 years of age 2Health News:CentriLogic Launches First Canadian-Based Distributed Cloud Computing Service 2Health News:CentriLogic Launches First Canadian-Based Distributed Cloud Computing Service 3
... These offer truly exceptional quality for this ... aberration has been dramatically improved with performance ... These objectives are also corrected for spherical ... entire 22mm field of view. The DL ...
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark...
... Designed for the scientist who wants ... the TE2000E2 is a high precision Z-focus ... This makes it possible to expand ... sources and image outputs. A five-way ...
... The IX71's modular ... provides 9 access ports ... output devices. Up to ... simultaneous access to a ...
Medicine Products: